These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16607967)

  • 41. Prevalence of herpes simplex virus type 1- and 2- specific antibodies among the acute, recurrent, and provoked types of female genital herpes.
    Hashido M; Lee FK; Nahmias AJ; Kawana T
    Microbiol Immunol; 1997; 41(10):823-7. PubMed ID: 9403510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.
    Cortesi R; Ravani L; Rinaldi F; Marconi P; Drechsler M; Manservigi M; Argnani R; Menegatti E; Esposito E; Manservigi R
    Int J Pharm; 2013 Jan; 440(2):229-37. PubMed ID: 22743007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. B7 costimulation molecules expressed from the herpes simplex virus 2 genome rescue immune induction in B7-deficient mice.
    Thebeau LG; Vagvala SP; Wong YM; Morrison LA
    J Virol; 2007 Nov; 81(22):12200-9. PubMed ID: 17804511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
    Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New concepts in herpes simplex virus vaccine development: notes from the battlefield.
    Dasgupta G; Chentoufi AA; Nesburn AB; Wechsler SL; BenMohamed L
    Expert Rev Vaccines; 2009 Aug; 8(8):1023-35. PubMed ID: 19627185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
    Pepose JS; Keadle TL; Morrison LA
    Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes?
    Mertz GJ; Rosenthal SL; Stanberry LR
    Sex Transm Dis; 2003 Oct; 30(10):801-2. PubMed ID: 14520182
    [No Abstract]   [Full Text] [Related]  

  • 52. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
    Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Status of vaccine research and development of vaccines for herpes simplex virus.
    Johnston C; Gottlieb SL; Wald A
    Vaccine; 2016 Jun; 34(26):2948-2952. PubMed ID: 26973067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interrupting transmission of genital herpes.
    Griffiths PD
    Rev Med Virol; 2004; 14(2):67-9. PubMed ID: 15026999
    [No Abstract]   [Full Text] [Related]  

  • 55. Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada.
    Romanowski B; Myziuk LN; Walmsley SL; Trottier S; Singh AE; Houston S; Joffe M; Chiu I
    Sex Transm Dis; 2009 Mar; 36(3):165-9. PubMed ID: 19098690
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genital herpes vaccine shows limited promise.
    Stephenson J
    JAMA; 2000 Oct; 284(15):1913-4. PubMed ID: 11035871
    [No Abstract]   [Full Text] [Related]  

  • 57. HSV-2: in pursuit of a vaccine.
    Johnston C; Koelle DM; Wald A
    J Clin Invest; 2011 Dec; 121(12):4600-9. PubMed ID: 22133885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.